Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE versus SYPRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE CODEINE PHOSPHATE versus SYPRINE.
PROMETHAZINE HYDROCHLORIDE; CODEINE PHOSPHATE vs SYPRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative via blockade of central and peripheral H1 receptors and antagonism of dopamine D2 receptors. Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, producing analgesia and cough suppression; it also has antitussive effects via central action.
Syprine (trientine hydrochloride) is a chelating agent that forms stable complexes with copper, thereby increasing urinary excretion of copper and reducing pathological copper accumulation in tissues.
Promethazine hydrochloride 6.25-25 mg / codeine phosphate 10-20 mg (based on codeine component) orally every 4-6 hours as needed. Maximum codeine dose: 60 mg per dose, 120 mg per day.
250 mg to 500 mg orally 4 times daily, maximum 2000 mg daily.
None Documented
None Documented
Promethazine: 10-19 hours (terminal); Codeine: 2.4-4 hours (terminal), prolonged in hepatic impairment. Clinical context: Dosing interval typically 4-6 hours for codeine; promethazine accumulates with repeated dosing.
Approximately 48 hours in healthy subjects, reflecting prolonged accumulation with regular dosing, requiring careful monitoring for toxicity.
Promethazine: Renal (70-80% as metabolites, <1% unchanged); Codeine: Renal (70-90% as metabolites, 5-15% unchanged). Biliary/feces: Minor (<10% total).
Primarily renal (approximately 50% unchanged within 24 hours after oral administration); biliary/fecal elimination accounts for a minor fraction (less than 10%).
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine